SCHEMBL19976836

SCHEMBL19976836

CC(C)CN/C(=N\C(=O)c1cccc(Cl)c1)Nc1n[nH]c2cc(Cl)c(F)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 7/20 0.41
GSK3B P49841 7/20 0.41
CYP1A2 P05177 2/20 0.41
CDK2 P24941 2/20 0.40
CDK1 P06493 1/20 0.40
HDAC6 Q9UBN7 3/20 0.39
ALPL P05186 1/20 0.39
LMNA P02545 1/20 0.39
MAPK3 P27361 1/20 0.38
CDC7 O00311 1/20 0.38
DAPK3 O43293 1/20 0.38
PAK4 O96013 1/20 0.38
FLT3 P36888 1/20 0.38
CSNK1A1 P48729 1/20 0.38
CLK2 P49760 1/20 0.38
CDK7 P50613 1/20 0.38
CDK9 P50750 1/20 0.38
PRKX P51817 1/20 0.38
CDK5 Q00535 1/20 0.38
DYRK1A Q13627 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19976789 0.91 GSK3B (0.42) MAPK1GSK3BCYP1A2CDK2CDK1
SCHEMBL19976821 0.89 HDAC6 (0.44) GSK3BCYP1A2HDAC6DYRK1AHDAC1
SCHEMBL19976776 0.83 GSK3B (0.48) MAPK1GSK3BCYP1A2HDAC6DYRK1A
SCHEMBL19976846 0.79 KDM4E (0.42) MAPK1GSK3BCDK2CDK1HDAC6
SCHEMBL19976729 0.79 HDAC6 (0.49) MAPK1GSK3BHDAC6HDAC1HDAC2
SCHEMBL16769265 0.79 GSK3B (0.43) GSK3BCYP1A2HDAC6DYRK1A
SCHEMBL16752864 0.79 GSK3B (0.46) GSK3BCYP1A2HDAC6DYRK1A
SCHEMBL16769266 0.79 GSK3B (0.46) GSK3BCYP1A2HDAC6DYRK1A
SCHEMBL16752862 0.79 GSK3B (0.46) GSK3BCYP1A2HDAC6DYRK1A
SCHEMBL19976866 0.79 DYRK1A (0.42) MAPK1GSK3BCYP1A2CDK2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9920012-B2 Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-03-20 US disclosed